<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37944696</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-7780</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</Title><ISOAbbreviation>J Infect Chemother</ISOAbbreviation></Journal><ArticleTitle>Pretransplant ribavirin and interferon-α therapy for rhinovirus interstitial pneumonia in a RAG1-deficient infant.</ArticleTitle><Pagination><StartPage>362</StartPage><EndPage>365</EndPage><MedlinePgn>362-365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiac.2023.11.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1341-321X(23)00275-1</ELocationID><Abstract><AbstractText>Severe combined immunodeficiency (SCID) is one of the most serious inborn errors of immunity leading to a fatal infection in early infancy. Allogeneic hematopoietic cell transplantation (HCT) or elective gene therapy prior to infection or live-attenuated vaccination is the current standard of curative treatment. Even in the era of newborn screening for SCID, pretransplant control of severe infection is challenging for SCID. Multiple pathogens are often isolated from immunocompromised patients, and limited information is available regarding antiviral strategies to facilitate curative HCT. We herein present a case of successfully controlled pretransplant pneumonia after ribavirin and interferon-α therapy in an infant with RAG1-deficiency. A four-month-old infant presented with severe interstitial pneumonia due to a co-infection of rhinovirus and Pneumocystis jirovecii. The tentative diagnosis of SCID prompted to start antibiotics and trimethoprim-sulfamethoxazole on ventilatory support. Because of the progressive respiratory failure four days after treatment, ribavirin and then pegylated interferon-α were started. He showed a drastic response to the treatment that led to a curative HCT 32 days after admission. This patient received the genetic diagnosis of RAG1-deficiency. Currently, he is an active 3-year-old boy with normal growth and development. The review of literature indicated that rhinovirus had a comparable or rather greater impact on the mortality of pediatric patients than respiratory syncytial virus. Considered the turn-around time to the genetic diagnosis of SCID, prompt ribavirin plus interferon-α therapy may help to control severe rhinovirus pneumonia and led to the early curative HCT for the affected infants.</AbstractText><CopyrightInformation>Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harada</LastName><ForeName>Nobutaka</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonoda</LastName><ForeName>Motoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishimura</LastName><ForeName>Masataka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: ischii-pediatr@kyudai.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eguchi</LastName><ForeName>Katsuhide</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Keishiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Wakato</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Emergency and Critical Care Center, Kyushu University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motomura</LastName><ForeName>Yoshitomo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaku</LastName><ForeName>Noriyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Emergency and Critical Care Center, Kyushu University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawaguchi</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Division of Pediatrics, Oita Prefectural Hospital, Oita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Takami</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Takeuchi Children's Clinic, Oita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohga</LastName><ForeName>Shouichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Infect Chemother</MedlineTA><NlmUniqueID>9608375</NlmUniqueID><ISSNLinking>1341-321X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018113" MajorTopicYN="Y">Respiratory Syncytial Virus, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018398" MajorTopicYN="N">Homeodomain Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Life-threatening pneumonitis</Keyword><Keyword MajorTopicYN="N">Newborn screening</Keyword><Keyword MajorTopicYN="N">Pegylated interferon-alpha-2a</Keyword><Keyword MajorTopicYN="N">Rotavirus vaccination</Keyword><Keyword MajorTopicYN="N">Severe combined immunodeficiency 5/6 key words</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>10</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>9</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37944696</ArticleId><ArticleId IdType="doi">10.1016/j.jiac.2023.11.003</ArticleId><ArticleId IdType="pii">S1341-321X(23)00275-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle>